Centessa Pharmaceuticals (CNTA) Common Equity (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Common Equity data on file, last reported at $487.3 million in Q1 2026.

• Common Equity for Q1 2026 came in at $487.3 million, up 26.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $487.3 million (up 26.18% YoY), and the FY2025 annual result was $526.9 million, up 31.21% from the prior year.
• Common Equity slipped to $487.3 million in Q1 2026 per CNTA's latest filing, from $526.9 million in the prior quarter.
• Over five years, Common Equity peaked at $526.9 million in Q4 2025 and troughed at $215.2 million in Q1 2024.
• A 5-year average of $360.3 million and a median of $344.9 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity surged 92.43% in 2024, then sank 39.58% in 2025.
• A 5-year view of Common Equity shows it stood at $336.2 million in 2022, then retreated by 29.72% to $236.2 million in 2023, then jumped by 69.97% to $401.5 million in 2024, then soared by 31.21% to $526.9 million in 2025, then retreated by 7.5% to $487.3 million in 2026.
• Business Quant data shows CNTA's Common Equity at $487.3 million in Q1 2026, $526.9 million in Q4 2025, and $301.6 million in Q3 2025.